<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03797495</url>
  </required_header>
  <id_info>
    <org_study_id>HISTORY</org_study_id>
    <nct_id>NCT03797495</nct_id>
  </id_info>
  <brief_title>Study of Individuals Affected With Hypoplasminogenemia</brief_title>
  <acronym>HISTORY</acronym>
  <official_title>Hypoplasminogenemia: An International RetroSpecTive and PrOspective CohoRt StudY (HISTORY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana Hemophilia &amp;Thrombosis Center, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione Angelo Bianchi Bonomi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana Hemophilia &amp;Thrombosis Center, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an Investigator initiated retrospective and prospective single cohort study. The&#xD;
      study will utilize an international registry and develop a specimen biobank to provide an&#xD;
      improved understanding of the natural history of hyposplasminogenemia, to elucidate the&#xD;
      heterogeneity of phenotypic expression, identify markers to predict disease course, and&#xD;
      inform improved therapeutic modalities&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aims of this study are to:&#xD;
&#xD;
        1. Define PLGD natural history in a large cohort of individuals with hypoplasminogenemia&#xD;
           and their first-degree family members.&#xD;
&#xD;
        2. Identify factors that correlate with disease expression and severity.&#xD;
&#xD;
        3. Create a specimen biobank for further studies, available to other researchers.&#xD;
&#xD;
      The project will be international in scope with two collaborating centers that have created&#xD;
      and will collect the subject data and samples. In North/Central/South America, the Indiana&#xD;
      Hemophilia &amp; Thrombosis Center (IHTC) will serve as the primary site while University of&#xD;
      Milan will serve as the center for all other sites. The database is housed at the University&#xD;
      of Milan, Italy.&#xD;
&#xD;
      Study population will include males and females affected with hyposplasminogenemia of any&#xD;
      age. Both one-year retrospective and three-year prospective data will be collected on an&#xD;
      international cohort of 100 affected individuals and their first degree family members&#xD;
      (parents, siblings; total estimated study population ~500).&#xD;
&#xD;
      Study sample analysis, except for urine analyses, will be centralized and performed in Italy;&#xD;
      the plasminogen antibody analysis will be batched for analysis, and the urine analyses will&#xD;
      be performed locally. A sample biorepository will be created and ultimately housed in Italy.&#xD;
      The study will provide testing for plasminogen activity and antigen, plasminogen genetic&#xD;
      analysis, polymorphisms in genes that impact plasminogen expression and fibrinolysis, and&#xD;
      global hemostatic assays. In addition, stored samples will be used for further testing and&#xD;
      analyses to potentially include whole genome sequencing to further identify plasminogen&#xD;
      genetic mutations as needed and to investigate other genetic modifiers of disease expression.&#xD;
      An exploratory aim includes investigating the potential relationship with streptococcal&#xD;
      strains and altered plasminogen products.&#xD;
&#xD;
      The study period will be 3 years for each enrolled subject. In-person visits will be&#xD;
      conducted and samples for analysis will be collected at baseline and at end of study.&#xD;
      Interval follow-up will be performed every 6 months by telephone. data will be collected at&#xD;
      unscheduled visits that are performed for clinical need at the treating physician's&#xD;
      discretion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2018</start_date>
  <completion_date type="Anticipated">June 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 18, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Define the natural history of plasminogen deficiency</measure>
    <time_frame>2 years</time_frame>
    <description>Recruit 100 subjects with hypoplasminogenemia and their first-degree family members&#xD;
Collect up to 1 year retrospective and 3 year prospective data on symptoms, treatment and interventions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify factors that contribute to or correlate with disease expression and severity</measure>
    <time_frame>5 years</time_frame>
    <description>Perform centralized plasminogen activity and antigen analyses&#xD;
Perform centralized genetic analysis to identify changes in the plasminogen gene&#xD;
Perform centralized analysis of polymorphisms that affect plasminogen activity levels and impact fibrinolysis&#xD;
Perform local urine analysis&#xD;
Collect samples to explore the interaction of altered plasminogen proteins with bacterial strains</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Create a specimen biobank</measure>
    <time_frame>15 years</time_frame>
    <description>Bank plasma, serum and DNA on consenting enrolled subjects</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Plasminogen Deficiency</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum, and plasma will be retained. Time perspective is retrospective and&#xD;
      prospective.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study population will include males and females affected with hyposplasminogenemia of any&#xD;
        age and their first degree family members (siblings and parents).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent and assent as applicable (Appendix 1)&#xD;
&#xD;
          2. A. Males or females with type 1 PD diagnosed locally with plasminogen activity levels&#xD;
             &lt;50% OR B. First degree family members of a person diagnosed with type 1 PD (includes&#xD;
             parents, siblings, half-siblings)&#xD;
&#xD;
          3. All ages included&#xD;
&#xD;
          4. Available clinical history and treatment for at least 1 year prior to entry except for&#xD;
             infants &lt; 1 year of age&#xD;
&#xD;
          5. Willingness to provide samples for analysis including DNA, plasma etc.&#xD;
&#xD;
          6. Willingness to participate in prospective follow-up for up to 3 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous organ transplant recipient&#xD;
&#xD;
          2. Any psychiatric disorder, other mental disorder, or any other medical disorder that&#xD;
             impairs the subject's ability to give informed consent or to comply with the&#xD;
             requirements of the study protocol&#xD;
&#xD;
          3. Refuses to provide informed consent&#xD;
&#xD;
          4. Special patient populations, including prisoners or, are deemed medically or&#xD;
             cognitively unsuitable for research by their treating physician&#xD;
&#xD;
          5. Inability to obtain a blood sample due to poor or limited venous access&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy D Shapiro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana Hemophilia &amp;Thrombosis Center, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Flora Peyvandi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univeristy of Milan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy D Shapiro, MD</last_name>
    <phone>317-871-0000</phone>
    <email>ashapiro@ihtc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charles Nakar, MD</last_name>
    <phone>317-871-0000</phone>
    <email>cnakar@ihtc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana Hemophila @Thrombosis Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neelam Thukral, CCRC</last_name>
      <phone>317-871-0000</phone>
      <phone_ext>373</phone_ext>
      <email>nthukral@ihtc.org</email>
    </contact>
    <contact_backup>
      <last_name>Charles Nakar, MD</last_name>
      <phone>317-871-0000</phone>
      <email>cnakar@ihtc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Amy D Shapiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Nakar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Children's Hematology-Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delia Darst</last_name>
      <phone>615-343-7190</phone>
      <email>delia.h.darst@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Heather McDaniel, MD, MSCI</last_name>
      <phone>615 936 1762</phone>
      <email>heather.mcdaniel@vumc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Heather McDaniel, MD, MSCI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Urbanek</last_name>
      <phone>682-885-1244</phone>
      <email>Heather.Urbanek@cookchildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Marcela Torres, MD</last_name>
      <phone>682 885 4007</phone>
      <email>marcela.torres@cookchildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Marcela Torres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Addy, RN, BSN, MPH</last_name>
      <phone>713-500-8352</phone>
      <email>Katherine.E.Addy@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nidra Rodriguez, MD</last_name>
      <phone>713 500 8360</phone>
      <email>Nidra.I.Rodriguez@uth.tmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nidra Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Britanico Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1280</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jhon A Avila, MD</last_name>
      <phone>549 114 187 9723</phone>
      <email>jaavilar@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jose M Ceresetto, MD</last_name>
      <phone>541 143 041 081</phone>
      <email>jceresetto@intramed.net</email>
    </contact_backup>
    <investigator>
      <last_name>Jose M Ceresetto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jhon A Avila, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Angelo Bianchi Bonomi Hemophilia and Thrombosis Center,</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marzia Menegatti, PhD</last_name>
      <phone>+39 - 02/50320727</phone>
      <email>marzia.menegatti@guest.unimi.it</email>
    </contact>
    <investigator>
      <last_name>Flora Peyvandi, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine, Chiang Mai University</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rungrote Natesirinilkul, MD</last_name>
      <phone>66 2 201 1749</phone>
      <email>rungrote.n@cmu.ac.th</email>
    </contact>
    <investigator>
      <last_name>Rungrote Natesirinilkul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istanbul University Cerrahpsasa, Cerrahpsasa Medical Faculty Pediatric Hematology and Oncology Department</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayse Gonca Kacar, MD</last_name>
      <phone>505 259 1229</phone>
      <email>goncakacar@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Tulin Celkan, MD</last_name>
      <phone>532 57 60723</phone>
      <email>tirajecelkan@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tulin Celkan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yuzuncu Yil University Faculty of Medicine Department of Ophthalmology</name>
      <address>
        <city>Van</city>
        <zip>65040</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammed Batur, MD</last_name>
      <phone>904 322 150 473</phone>
      <phone_ext>6030</phone_ext>
      <email>muhammedbatur@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Muhammed Batur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Italy</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Shapiro AD, Menegatti M, Palla R, Boscarino M, Roberson C, Lanzi P, Bowen J, Nakar C, Janson IA, Peyvandi F. An international registry of patients with plasminogen deficiency (HISTORY). Haematologica. 2020 Mar;105(3):554-561. doi: 10.3324/haematol.2019.241158. Epub 2020 Jan 30. Review.</citation>
    <PMID>32001536</PMID>
  </reference>
  <results_reference>
    <citation>Tait RC, Walker ID, Conkie JA, Islam SI, McCall F, Mitchell R, Davidson JF. Plasminogen levels in healthy volunteers--influence of age, sex, smoking and oral contraceptives. Thromb Haemost. 1992 Nov 10;68(5):506-10.</citation>
    <PMID>1455395</PMID>
  </results_reference>
  <results_reference>
    <citation>Schuster V, HÃ¼gle B, Tefs K. Plasminogen deficiency. J Thromb Haemost. 2007 Dec;5(12):2315-22. Epub 2007 Sep 26. Review.</citation>
    <PMID>17900274</PMID>
  </results_reference>
  <results_reference>
    <citation>Ma Q, Ozel AB, Ramdas S, McGee B, Khoriaty R, Siemieniak D, Li HD, Guan Y, Brody LC, Mills JL, Molloy AM, Ginsburg D, Li JZ, Desch KC. Genetic variants in PLG, LPA, and SIGLEC 14 as well as smoking contribute to plasma plasminogen levels. Blood. 2014 Nov 13;124(20):3155-64. doi: 10.1182/blood-2014-03-560086. Epub 2014 Sep 10.</citation>
    <PMID>25208887</PMID>
  </results_reference>
  <results_reference>
    <citation>Celkan T. Plasminogen deficiency. J Thromb Thrombolysis. 2017 Jan;43(1):132-138. doi: 10.1007/s11239-016-1416-6. Review.</citation>
    <PMID>27629020</PMID>
  </results_reference>
  <results_reference>
    <citation>Shapiro AD, Nakar C, Parker JM, Albert GR, Moran JE, Thibaudeau K, Thukral N, Hardesty BM, Laurin P, Sandset PM. Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency. Blood. 2018 Mar 22;131(12):1301-1310. doi: 10.1182/blood-2017-09-806729. Epub 2018 Jan 10.</citation>
    <PMID>29321155</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 28, 2018</study_first_submitted>
  <study_first_submitted_qc>January 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2019</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana Hemophilia &amp;Thrombosis Center, Inc.</investigator_affiliation>
    <investigator_full_name>Amy D Shapiro, MD</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

